HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (24) Citing Articles via Google Scholar Google Scholar Articles by Merz, J. F. Search for Related Content PubMed PubMed Citation Articles by Merz, J. F. Related Collections Molecular Diagnostics and Genetics Evidence Based Laboratory Medicine and Test Utilization

Disease Gene Patents: Overcoming Unethical Constraints on Clinical Laboratory Medicine

^a Address for correspondence: Center for Bioethics, University of Pennsylvania, 3401 Market St., Suite 320, Philadelphia, PA 19104-3308. Fax 215-573-4931; e-mail merz{at}mail.med.upenn.edu

Abstract

The rapidly growing number of disease gene patents—patents that claim all methods for diagnosis of a particular genetic condition—threatens the ability of physicians to provide medical care to their patients. In the past, patented diagnostic tests were made broadly available to the medical community in the form of test kits or licenses to use the patented test. Disease gene tests, however, are being monopolized by a small number of providers. Monopolization of medical testing services: (a) threatens to restrict research activities; (b) creates unacceptable conflicts of interest; (c) may reduce patient access to testing; (d) may lead to inequitable extensions of patent terms on tests and related discoveries; and (e) grants to patent holders the ability to dictate the standard of care for testing, and to otherwise interfere with the practice of medicine. Because of the risks raised by monopolization, amendment of the patent law to require compulsory licensing of physicians providing medical services is recommended. © 1999 American Association for Clinical Chemistry

The following articles in journals at HighWire Press have cited this article:

				M Ladanyi Translating research into cancer molecular diagnostics and patents J. Clin. Pathol., August 1, 2005; 58(8): 793 - 794. [Full Text] [PDF]

				R. Dalpe, L. Bouchard, A.-J. Houle, and L. Bedard Watching the Race to Find the Breast Cancer Genes Science Technology Human Values, April 1, 2003; 28(2): 187 - 216. [Abstract] [PDF]

				R. Gold, T. A. Caulfield, and P. N. Ray Gene patents and the standard of care Can. Med. Assoc. J., August 1, 2002; 167(3): 256 - 257. [Full Text] [PDF]

				D. J. Willison and S. M. MacLeod Patenting of genetic material: Are the benefits to society being realized? Can. Med. Assoc. J., August 1, 2002; 167(3): 259 - 262. [Full Text] [PDF]

				D. G.B. Leonard Improved Method for Diagnosis of Charcot-Marie-Tooth Type 1A: Patent Pending? Clin. Chem., May 1, 2001; 47(5): 807 - 808. [Full Text] [PDF]

				R. Kneller Technology Transfer: A Review for Biomedical Researchers Clin. Cancer Res., April 1, 2001; 7(4): 761 - 774. [Abstract] [Full Text]

				R. A. Hegele, J. F. Merz, and L. M. Silverman Uncovering Rare Mutations: An Unforeseen Complication of Routine Genotyping of APOE • J. Merz and L. Silverman provide the following comment: Clin. Chem., September 1, 1999; 45(9): 1579 - 1581. [Full Text] [PDF]

				D. S. Young and D. G.B. Leonard Issues in Genetic Testing Clin. Chem., June 1, 1999; 45(6): 915 - 926. [Full Text] [PDF]

				D. S. Young Issues in Genetic Testing Clin. Chem., May 1, 1999; 45(5): 725 - 725. [Full Text] [PDF]